Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow PLX by emailGet an email when PLX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PLX, unsubscribe in one click. Privacy
📣 What PLX Says Is Next
second half of 2027 · “The Company continues to anticipate top ‑ line results in the second half of 2027. Focus on Rare Renal Indications (Preclinical Programs)”
Company press release, Aug 12, 2026 · SEC filing
second half of 2027 · “PRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027”
Company press release, Aug 12, 2026 · SEC filing
2H 2027 · “Top-line results anticipated in 2H 2027 PRX-115 Phase 1 outcome”
Company press release, May 21, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full PLX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PLX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.